Ulcerative Colitis: Natural History and Medical Management

Current Surgery

Volumn 58, Issue 2, 2001, Pages 195-197

  Cabrera, Kimiye ^a   Schwartz, Richard W ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0347078638     PISSN: 01497944     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7944(00)00470-0     Document Type: Short Survey

References (22)

1. Pena AS, Crusius AB. Genetics of inflammatory bowel disease: implications for the future. World J Surg. 1998; 22:390-393.
2. Satsangi J, Welsh KI, Bunce M, et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet. 1996;347:1212.
3. Nixon JB, Burdick JS, Mirza AH. Premalignant changes in ulcerative colitis. Semin Surg Oncol. 1995;11:386-393.
4. Rice HE, Chuang E. Current management of pediatric inflammatory bowel disease. Semin Pediatr Surg. 1999;8: 221-228.
5. Roy MA. Inflammatory bowel disease. Surg Clin North Am. 1997;77:1419-1431.
6. Robinson M. Medical therapy of inflammatory bowel disease for the 21st century. Eur J Surg Suppl. 1998;582:90-98.
7. George J, Present DH, Pou R, Bodian C, Rubin PH. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol. 1996;9:1711-1714.
8. Treem WR, Cohen J, Davis PM, Justinich CJ, Hyams JS. Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery. Dis Colon Rectum. 1995;38:474-479.
9. Turunen U, Farkkila M, Hakala K, et al. A double-blind, placebo-controlled, six month ciprofloxacin treatment improves prognosis in ulcerative colitis. Gastroenterology. 1994;106:A1104.
10. Sternthal M, George J, Kornbluth A, Lichtiger D, Present D. Toxicity associated with the use of cyclosporine in patients with inflammatory bowel disease. Gastroenterology. 1996;110:A1019.
11. Horgan K. Initial experience with mycophenolate mofetilin in the treatment of severe inflammatory bowel disease. Gastroenterology. 1997;112:A999.
12. Belluzi A, Boschi S, Brignola C, Munarini A, Cariani G, Miglio F. Polyunsaturated fatty acids and inflammatory bowel disease. Am J Clin Nutr. 2000;71(suppl 1):339s-342s.
13. Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg. 1998;22:382-389.
14. D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histologic healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology. 1999; 116: 1029-1034.
15. Hulten L. Proctocolectomy and ileostomy to pouch surgery for ulcerative colitis. World J Surg. 1998;22:335-341.
16. Ekbom A. Risk of cancer in ulcerative colitis. J Gastrointest Surg. 1998;2:312-313.
17. The Society for Surgery of the Alimentary Tract, American Gastroenterological Association, American Society for Liver Diseases, American Society for Gastrointestinal Endoscopy, American Hepato-Pancreato-Biliary Association. Ulcerative colitis and colon carcinoma: epidemiology, surveillance, diagnosis and treatment. J Gastrointest Surg. 1998;2:305-306.
18. Riddell RH. How reliable/valid is dysplasia at identifying at-risk patients with ulcerative colitis? J Gastrointest Surg. 1998;2:314-317.
19. Solomon MJ, Schnitzler M. Cancer and inflammatory bowel disease: bias, epidemiology, surveillance, and treatment. World J Surg. 1998;22:352-358.
20. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy and ulcerative colitis? Lancet. 1994;343(8889):71-74.
21. Lashner BA, Shapiro BD. Biology of colorectal surgery in ulcerative colitis. J Gastrointest Surg. 1998;2:307-311.
22. Bernstein CN. How do we assess the value of surveillance techniques in ulcerative colitis? J Gastrointest Surg. 1998; 2:318-321.